Top news of the week: 16.02.2022.
Startups
How the biotech downturn is already affecting drug startups
At an industry conference Monday, a group of venture investors noted changes in how long biotechs are taking to raise money, and a shifting outlook among investors who specialize in ...
Venture Investment Trends in Biotech
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services.
Lilly, Pfizer-backed Arkuda bags $64M to test drug in frontotemporal dementia in 2023
Arkuda Therapeutics will use a $64 million series B to bankroll studies that tee up the biotech's lead program for a late-2023 clinical entry. The biotech is going after a protein crucial ...
Ex-FDA interim chief Giroir rejoins biotech world with eyes on $50M fundraising for new infectious disease company
Former FDA Acting Commissioner and Admiral Brett Giroir, M.D., is back in the private sector and jumping into securing a series A for his latest biotech. Altesa BioSciences, which broke ...
Good Day BIO: Biotech unites on CMS coverage decision
Ending the week with what biotech's saying about the CMS decision regarding Aduhelm, how biotech can make fashion more sustainable, and more on California’s new legislation to reinstate key ...
Califf's confirmation as FDA chief gives biopharma industry a 'steady hand' at the agency: analyst
By a narrow vote of 50-46, Robert Califf has been confirmed by the Senate to run the FDA. Analysts at RBC Capital Markets applauded the confirmation, saying Califf can bring regulatory ...
Rethinking the Cell Therapy Business: Derrell Porter of Cellevolve on The Long Run
Today’s guest on The Long Run is Derrell Porter. Derrell is the founder and CEO of San Francisco-based Cellevolve. This is a different kind of biotech startup. Most startups are all about ...
Fierce Pharma Asia—Lilly, Innovent’s PD-1 saga; Biogen, Eisai’s Aduhelm rebuttal; Surprise FDA foreign inspections?
Eli Lilly and Innovent Biologics' PD-1 application hit a tough FDA review. Biogen and Eisai launched a formal attack on Medicare's proposed Aduhlem coverage policy. GAO advised the FDA to ...